Nithin Kamath questions India's slow adoption of affordable GLP-1 weight-loss drugs, despite rising obesity. He points to challenges like l...

Initial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...

The National Family Health Survey 2023-24 reveals India's success in expanding welfare delivery and essential service access, reaching near...

Young Indian professionals, particularly in IT and finance, are facing a heart disease crisis due to unhealthy lifestyles. Leading cardiac ...

Discover "Hara Hachi Bu," a centuries-old Japanese practice from Okinawa, teaching to eat until 80% full. This simple principle, passed thr...

Veteran actor Anupam Kher, aged 71, showcases remarkable fitness. A recent workout video went viral, impressing fans. Kher shared his diet,...

India's latest health survey reveals significant improvements in maternal care and child vaccination rates. Stunting among children has see...

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...

Cipla has appointed Shivam Puri as the new Chief Executive Officer for its One India Business. This significant leadership change will take...

Rising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...

India faces a health challenge before achieving wealth. Chief Economic Advisor V Anantha Nageswaran points to rising obesity and sedentary ...

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...

With an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

The landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...